Mysler E, Sidiropoulos PI, Balanescu A, Detert J, et al. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study. Ann Rheum Dis 2026 Apr 15:S0003-4967(26)00198-6. doi: 10.1016/j.ard.2026.
PMID: 41991443